eResearchTechnology Inc.

eResearchTechnology Inc. provides endpoint technology services tailored for clinical trial management, enhancing data quality through advanced solutions and comprehensive software offerings catering to pharmaceutical and biotech sectors. Founded in 1972 and headquartered in Philadelphia, US, eResearchTechnology Inc. specializes in clinical trial management solutions.

In 2020, a consortium co-led by Astorg and Nordic Capital, along with Novo Holdings, Partners Group, and the company’s management, invested in eResearchTechnology Inc. In April 2021, BioClinica Inc. , a portfolio company of Cinven, and eResearchTechnology Inc. , a portfolio company of Astorg, Nordic Capital, Partners Group and Novo Holdings, merged to form Clario.

eResearchTechnology Inc. offers a comprehensive suite of endpoint technology services designed for clinical trial management. Their core products include clinical trial management software, connected devices, and AI-driven solutions that cater to areas such as Cardiac Safety, eCOA, Medical Imaging, Precision Motion, and Respiratory health. The solutions support data collection and analysis in trials conducted across over 100 countries, helping pharmaceutical companies, biotech firms, and medical device manufacturers streamline their processes and enhance patient outcomes.

The company generates its revenue through service contracts and partnerships with various stakeholders in the clinical trial ecosystem, primarily focusing on B2B engagements with pharmaceutical and biotechnology companies. Looking ahead, eResearchTechnology Inc. plans to expand its product offerings and enter new markets. This includes the development of new technologies designed to enhance clinical trial efficiency and outcomes.

The recent funding round will support these initiatives, particularly the advancement of their endpoint technology solutions. Additionally, the company is targeting expansion into emerging markets, leveraging its established presence to tap into new opportunities. Following Blum Capital Partners' exit, the company is positioned to continue its growth trajectory in the evolving clinical trial landscape.